These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21339433)

  • 1. Casopitant and ondansetron for postoperative nausea and vomiting prevention in women at high risk for emesis: a phase 3 study.
    Altorjay A; Melson T; Chinachoit T; Kett A; Aqua K; Levin J; Blackburn LM; Lane S; Pergolizzi JV
    Arch Surg; 2011 Feb; 146(2):201-6. PubMed ID: 21339433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients.
    Singla NK; Singla SK; Chung F; Kutsogiannis DJ; Blackburn L; Lane SR; Levin J; Johnson B; Pergolizzi JV
    Anesthesiology; 2010 Jul; 113(1):74-82. PubMed ID: 20526194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
    Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM
    Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
    Herrstedt J; Apornwirat W; Shaharyar A; Aziz Z; Roila F; Van Belle S; Russo MW; Levin J; Ranganathan S; Guckert M; Grunberg SM
    J Clin Oncol; 2009 Nov; 27(32):5363-9. PubMed ID: 19805683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A risk adapted approach reduces the overall institutional incidence of postoperative nausea and vomiting.
    Biedler A; Wermelt J; Kunitz O; Müller A; Wilhelm W; Dethling J; Apfel CC
    Can J Anaesth; 2004 Jan; 51(1):13-9. PubMed ID: 14709454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of transdermal scopolamine on the incidence and severity of postoperative nausea and vomiting in a group of high-risk patients given prophylactic intravenous ondansetron.
    Jones S; Strobl R; Crosby D; Burkard JF; Maye J; Pellegrini JE
    AANA J; 2006 Apr; 74(2):127-32. PubMed ID: 16617916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, multicenter trial comparing transdermal scopolamine plus ondansetron to ondansetron alone for the prevention of postoperative nausea and vomiting in the outpatient setting.
    Gan TJ; Sinha AC; Kovac AL; Jones RK; Cohen SA; Battikha JP; Deutsch JS; Pergolizzi JV; ; Glass PS
    Anesth Analg; 2009 May; 108(5):1498-504. PubMed ID: 19372328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haloperidol vs. ondansetron for the prevention of postoperative nausea and vomiting following gynaecological surgery.
    Aouad MT; Siddik-Sayyid SM; Taha SK; Azar MS; Nasr VG; Hakki MA; Zoorob DG; Baraka AS
    Eur J Anaesthesiol; 2007 Feb; 24(2):171-8. PubMed ID: 16938159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting.
    Roila F; Rolski J; Ramlau R; Dediu M; Russo MW; Bandekar RR; Grunberg SM
    Ann Oncol; 2009 Nov; 20(11):1867-73. PubMed ID: 19541792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting.
    Gan TJ; Apfel CC; Kovac A; Philip BK; Singla N; Minkowitz H; Habib AS; Knighton J; Carides AD; Zhang H; Horgan KJ; Evans JK; Lawson FC;
    Anesth Analg; 2007 May; 104(5):1082-9, tables of contents. PubMed ID: 17456656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rolapitant for the prevention of postoperative nausea and vomiting: a prospective, double-blinded, placebo-controlled randomized trial.
    Gan TJ; Gu J; Singla N; Chung F; Pearman MH; Bergese SD; Habib AS; Candiotti KA; Mo Y; Huyck S; Creed MR; Cantillon M;
    Anesth Analg; 2011 Apr; 112(4):804-12. PubMed ID: 21385988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of orally disintegrating ondansetron in preventing postoperative nausea and vomiting after laparoscopic cholecystectomy: a randomised, double-blind placebo controlled study.
    Grover VK; Mathew PJ; Hegde H
    Anaesthesia; 2009 Jun; 64(6):595-600. PubMed ID: 19453311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevention and treatment of postoperative nausea and vomiting (results of a multicenter study)].
    Buniatian AA; Mizikov VM; Pavlova ZSh
    Anesteziol Reanimatol; 2004; (5):22-7. PubMed ID: 15573720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of ondansetron with ondansetron and dexamethasone in prevention of PONV in diagnostic laparoscopy.
    Rajeeva V; Bhardwaj N; Batra YK; Dhaliwal LK
    Can J Anaesth; 1999 Jan; 46(1):40-4. PubMed ID: 10078401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why no casopitant-only arm?
    Anixter MB
    Anesthesiology; 2011 Jan; 114(1):224-5; author reply 225. PubMed ID: 21178684
    [No Abstract]   [Full Text] [Related]  

  • 16. Dexamethasone plus ondansetron for prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a comparison with dexamethasone alone.
    Bano F; Zafar S; Aftab S; Haider S
    J Coll Physicians Surg Pak; 2008 May; 18(5):265-9. PubMed ID: 18541078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities.
    Navari RM
    Curr Opin Investig Drugs; 2008 Jul; 9(7):774-85. PubMed ID: 18600583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic control of post-operative nausea and vomiting using ondansetron and ramosetron after cardiac surgery.
    Choi DK; Chin JH; Lee EH; Lim OB; Chung CH; Ro YJ; Choi IC
    Acta Anaesthesiol Scand; 2010 Sep; 54(8):962-9. PubMed ID: 20626355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blinded comparison of ondansetron, granisetron, and placebo for prevention of postoperative nausea and vomiting after supratentorial craniotomy.
    Jain V; Mitra JK; Rath GP; Prabhakar H; Bithal PK; Dash HH
    J Neurosurg Anesthesiol; 2009 Jul; 21(3):226-30. PubMed ID: 19543000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.